| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8812600 | The Journal of Pediatrics | 2018 | 6 Pages |
Abstract
The use of BIG-IV since its licensure in 2003 treated approximately 93% of US patients with laboratory-confirmed infant botulism, and prevented >65 years in hospital stay and >$85 million in hospital charges from occurring. The greatest LOS reduction was achieved when BIG-IV was administered soon after hospital admission. Effective and appropriate use of BIG-IV in the US has continued in the postlicensure period.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Perinatology, Pediatrics and Child Health
Authors
Jessica R. MPH, Jessica M. MD, Nicholas P. PhD, Stephen S. MD, MPH,